These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25375273)

  • 1. Understanding the adverse effects of ocriplasmin - reply.
    Johnson MW; Fahim AT
    JAMA Ophthalmol; 2015 Feb; 133(2):230. PubMed ID: 25375273
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding the adverse effects of ocriplasmin.
    Beebe DC
    JAMA Ophthalmol; 2015 Feb; 133(2):229. PubMed ID: 25376025
    [No Abstract]   [Full Text] [Related]  

  • 3. Understanding the adverse effects of ocriplasmin - reply.
    Tibbetts MD; Reichel E; Witkin AJ
    JAMA Ophthalmol; 2015 Feb; 133(2):229-30. PubMed ID: 25375214
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe art thou?
    Kim JE
    JAMA Ophthalmol; 2014 Apr; 132(4):379-80. PubMed ID: 24577332
    [No Abstract]   [Full Text] [Related]  

  • 5. Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography.
    Tibbetts MD; Reichel E; Witkin AJ
    JAMA Ophthalmol; 2014 Apr; 132(4):487-90. PubMed ID: 24577286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection.
    Fahim AT; Khan NW; Johnson MW
    JAMA Ophthalmol; 2014 Apr; 132(4):484-6. PubMed ID: 24577241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute ocriplasmin retinopathy.
    Johnson MW; Fahim AT; Rao RC
    Retina; 2015 Jun; 35(6):1055-8. PubMed ID: 25996428
    [No Abstract]   [Full Text] [Related]  

  • 8. Early panretinal abnormalities on fundus autofluorescence and spectral domain optical coherence tomography after intravitreal ocriplasmin.
    Barteselli G; Carini E; Invernizzi A; Ratiglia R; Viola F
    Acta Ophthalmol; 2016 Mar; 94(2):e160-2. PubMed ID: 26010219
    [No Abstract]   [Full Text] [Related]  

  • 9. Transient vision loss after ocriplasmin injection.
    Reiss B; Smithen L; Mansour S
    Retina; 2015 Jun; 35(6):1107-10. PubMed ID: 25901839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute loss of vision after an intravitreal injection ocriplasmin: a functional evolutionary study for 1-year follow-up.
    Gómez-Ulla F; Bande MF; Abraldes M
    Doc Ophthalmol; 2015 Dec; 131(3):231-5. PubMed ID: 26542118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.
    Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU
    Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin.
    Luttrull JK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography.
    Itoh Y; Kaiser PK; Singh RP; Srivastava SK; Ehlers JP
    Ophthalmology; 2014 Dec; 121(12):2506-2507.e2. PubMed ID: 25208855
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction.
    Kaiser PK; Kampik A; Kuppermann BD; Girach A; Rizzo S; Sergott RC
    Retina; 2015 Jun; 35(6):1111-27. PubMed ID: 25635577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocriplasmin: nonsurgical option for VMA and macular hole, but with potential barriers to practical use.
    Ober MD; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(2):113-6; discussion p.113. PubMed ID: 23510035
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology.
    Willekens K; Abegão Pinto L; Vandewalle E; Stalmans I; Stalmans P
    Retina; 2015 Jun; 35(6):1135-43. PubMed ID: 25719990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flat Electroretinography and Acute Visual Loss After Ocriplasmin Injection for Vitreomacular Adhesion Complicating Macular Schisis.
    Hale BP; Au AK; Falk NS; Bhatnagar P; Beer PM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Sep; 46(8):888-92. PubMed ID: 26431307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incomplete release of vitreomacular attachments after intravitreal ocriplasmin.
    Jeng KW; Baumal CR; Witkin AJ; Witkin SR; Wiegand TW; Waheed NK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):271-4. PubMed ID: 25707057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel possibility of vitreomacular traction treatment.
    Michalska-Małecka K; Witek K; Sierocka-Stępień J; Wyględowska-Promieńska D; Nowak M
    Acta Ophthalmol; 2016 Dec; 94(8):e818-e819. PubMed ID: 27167161
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute vision loss after ocriplasmin use.
    Reiss B; Smithen L; Mansour S
    Retin Cases Brief Rep; 2015; 9(2):168-9. PubMed ID: 25741635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.